Studies of Inherited Diseases of Metabolism
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001345 |
Recruitment Status :
Recruiting
First Posted : November 4, 1999
Last Update Posted : April 13, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Diseases of mineral metabolism such as familial multiple endocrine neoplasia type 1 (FMEN1), familial hypocaliuric hypercalcemia (FHH), familial hyperparathyroidism (FH), and pseudohypoparathyroidism (PHP) are known as hereditary abnormalities. Meaning these conditions are passed from parents to their children through genes. These specific conditions result in abnormal levels of calcium in the blood.
This study was designed to help researchers understand more about the genes that are responsible for these disorders. By learning more about the genetic process involved in hereditary abnormalities, new tests and treatments can be developed.
Subjects for this study will be members of families that have had relatives diagnosed with a disease of mineral metabolism. Participants will be asked to give blood samples for DNA extraction. DNA is the part of cells that carries genetic information.
The DNA will be analyzed and the results given to the subjects. Genetic counseling will be provided to subjects to aid in interpreting their results.
Condition or disease |
---|
Multiple Endocrine Neoplasia |
Study Type : | Observational |
Estimated Enrollment : | 2000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Family Studies in Metabolic Diseases and Mineral Metabolism |
Actual Study Start Date : | August 19, 1993 |

Group/Cohort |
---|
1
members of families that have had relatives diagnosed with a disease of mineral metabolism
|
- Evaluation of metabolic diseases [ Time Frame: Yearly ]Studies will be focused around forms of hereditary hypercalcemia, MEN1, FHH, HPT-JT, and FIHP as well as other disorders of mineral metabolism like PHP. In doing so, we will test the hypothesis that MEN1 and MEN1-like states develop as a result of a germ line mutation in MEN1 or a CDKI gene, define the mutations present in the affected members of MEN1 kindreds, and assess the frequency of such mutations in patients with apparently sporadic disease.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
- ELIGIBILITY CRITERIA:
Patients with known or suspected metabolic disorders of such as MEN 1, MEN 1-like states, FHH, HPT-JT, FIH, FIC, PHP and their first degree relatives (parents, siblings and offspring) and spouses. For the most part only one index case in a family will be tested.
Patient has possible form of familial hyperparathyroidism. Or case is a clinically unaffected first degree relative of such a patient.
There is no lower age limit to enter a clinically affected minor into the study. However, asymptomatic and possibly unaffected cases will not be enrolled.
A pregnant woman could be included in aspects of the research study that present no greater than minimal risk to patient or fetus, such as DNA testing of maternal blood.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001345
Contact: Craig S Cochran, R.N. | (301) 402-1880 | craigc@bdg10.niddk.nih.gov | |
Contact: Smita Jha, M.D. | (301) 827-1930 | smita.jha@nih.gov |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 | |
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov |
Principal Investigator: | Smita Jha, M.D. | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Publications:
Responsible Party: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00001345 |
Other Study ID Numbers: |
930127 93-DK-0127 |
First Posted: | November 4, 1999 Key Record Dates |
Last Update Posted: | April 13, 2021 |
Last Verified: | April 9, 2021 |
Hypercalcemia Multiple Endocrine Neoplasia (MEN) Familial Hypocalciuric Hypercalcemia Hyperparathyroidism Linkage Analysis |
Neoplasms Endocrine Gland Neoplasms Multiple Endocrine Neoplasia Neoplasms by Site |
Endocrine System Diseases Neoplasms, Multiple Primary Neoplastic Syndromes, Hereditary Genetic Diseases, Inborn |